Sign Up! | Tags | Domains | Statistics | Options | Advanced Search
|
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
fiercebiotech.com » Untitled News Source - Nov 4, 2008
France's NicOx announced positive results from a 118 patient blood pressure trial, which compared its experimental arthritis drug naproxcinod and a traditional painkiller, naproxen, in osteoarthritis patients with …
Also tagged: nicox, clinical trial results, naproxcinod
fiercebiotech.com » Untitled News Source - Oct 27, 2008
Shares of Savient Pharmaceuticals cratered after the developer announced that five patients experienced heart problems while taking the drug pegloticase in two trials. Its stock plunged 71 percent on the news, with …
Also tagged: drug safety, savient pharmaceuticals, biotech stock, clinical trial results
fiercebiotech.com » Untitled News Source - Oct 27, 2008
Novartis says that a single dose of ACZ885 produced "rapid and long-lasting remission" in children and adults suffering from rare forms of arthritis. The pharma giant presented late-stage data on the drug, which is …
Also tagged: novartis, clinical trial results, acz885
fiercebiotech.com » Untitled News Source - Oct 14, 2008
With a Phase III trial scheduled for next year, Research Triangle Park, NC-based Tranzyme Pharma says it is now pondering three key avenues to go forward: partner the drug, raise $60 million from investors or sell the …
Also tagged: deals, mergers and acqusitions, tranzyme pharma, tzp 101
thaindian.com » Thaindian News - Oct 13, 2008
Peshawar , Oct 13 (ANI): Amid unconfirmed reports about the recovery of the missing Afghan ambassador-designate Abdul Khaliq Farahi, Pakistani law enforcement agencies have said that they were still searching for him …
Also tagged: national, ahmed, ambassador, abducted, nook, diplomat, few days, law enforcement agencies, couple of days, pakistan government, police official, armed men, abdul khaliq, continuous pressure, pakistani law
fiercebiotech.com » Untitled News Source - Aug 20, 2008
Fresh on the heels of its Phase III disaster with the Alzheimer's drug Flurizan, Myriad Genetics announced that it has brought in JPMorgan Chase to help it conduct a strategic review. The developer is considering a …
Also tagged: alzheimer and 039 s, myriad genetics, flurizan, h lundbeck
fiercebiotech.com » Untitled News Source - Aug 19, 2008
Vertex and partner Johnson & Johnson have struck agreements with regulators on both sides of the Atlantic for a new Phase III trial of the closely-watched telaprevir for hepatitis C. This new late-stage study will …
Also tagged: johnson and johnson, hepatitis c, vertex, telaprevir
fiercebiotech.com » Untitled News Source - Aug 18, 2008
Shares of Dyax were on a roll in premarket trading after the company announced that its lead drug hit its primary endpoint in a late-stage trial for a genetic blood disorder. Researchers said that 93.8 percent of the …
Also tagged: dyax, hae, henry e blair, dx 88
fiercebiotech.com » Untitled News Source - Aug 12, 2008
Hitting a primary endpoint in a late-stage trial is not always a recipe for success, it seems. Shares of Altus Pharmaceuticals nosedived this morning after the company issued a release saying that its late-stage study …
Also tagged: altus pharmaceuticals, trizytek
fiercebiotech.com » Untitled News Source - Jun 13, 2008
Outside experts are preparing to review ustekinumab, Centocor's injectable treatment for severe psoriasis. Two Phase III studies demonstrated positive results, but staffers will have to consider possible increased risk …
Also tagged: fda, new drugs, johnson and johnson, psoriasis, biologics, biotech drugs, ustekinumab